## **Egyptian Herbal Monograph**

Volume 3

# Medicinal plants used in Egypt

Egyptian Drug Authority (EDA)

2024





# Egyptian Herbal Monograph

### **Medicinal Plants Used in Egypt**

Ginkgo biloba L.

چنکو

#### 1. Names & Synonyms (1)

*Ginkgo biloba* L. Family: Ginkgoaceae. Syns. Pterophyllus salisburiensis Nelson, Salisburia adiantifolia Smith, S. macrophylla C.Koch

**Arabic:** Ginkgo چنکو

**English**: Ginkgo leaf (2), Fossil tree; Kew tree; Maidenhair tree (3).

#### 2. Parts used for medicinal purpose

Dried leaf (1, 3-5).

#### 3. Major chemical constituents

- **Flavonoids**: Flavonols (quercetin, kaempferol, isorhamnetin, and their glycosides and coumaroyl esters) (6), proanthocyanidins (yield delphinidin and cyanidin as main building blocks after acid hydrolysis) (7, 8).
- Terpene lactones: Bilobalide, ginkgolides A, B, C, J, M (6).
- **Amino acids:** 6-Hydroxykynurenic acid (2-carboxy-4-one-6- hydroxyquinoline), a metabolite of tryptophan (9).
- **Others**: Benzoic acid, ginkgolic acid, 2-hexenal, polyprenols (e.g. di-trans-poly-cis-octadecaprenol) and acidic polysaccharide (10).

#### 4. Medicinal uses (Indications)

- **A.** Improvement of (age-associated) cognitive impairment and of quality of life in mild dementia (1, 4, 5). Also helps to enhance cognitive function and memory in adults (11).
- **B.** Improvement of peripheral arterial occlusive disease particularly intermittent claudication (poor circulation to the lower legs), and vertigo tinnitus of vascular origin (2, 3, 5).
- **C.** Relief of heaviness of legs and the sensation of cold hands and feet associated with minor circulatory disorders, after serious conditions have been excluded by a medical doctor (4, 11).



#### 5. Herbal preparations correlated to medicinal use (4)

- **1.** Powdered herbal substance.
- 2. Dry extract, extraction solvent: acetone 60% m/m<sup>3</sup>, (extraction ratio 35-67:1) (1)

Herbal preparations are in pharmaceutical dosage forms. The pharmaceutical form should be described by the Pharmacopoeia full standard term.

#### 6. Posology and method of administration correlated to medicinaluse

#### **Preparation 1 Indication C**

Adults and elderly Single dose: 250-360 mg, daily dose: 750 mg (4).

#### **Duration of use**

If the symptoms persist for more than 2 weeks, a doctor or a pharmacist should beconsulted.

#### Preparation 2 Indication A Adults and elderly:

120–240 mg daily in 2 - 3 divided doses (1, 12).

#### Indication **B**

120–160 mg daily in 2 - 3 divided doses (3, 12).

#### Duration of use (4)

Treatment should last for at least 8 weeks. If there is no symptomatic improvement after 3 months, or if pathological symptoms should intensify, the doctor should check whether continuation of treatment is still justified.

Method of administration (4): Oral use.

#### 7. Contraindications

- Hypersensitivity to active substances and to other plants of the same family.
- The use is contraindicated in pregnancy (4).
- The use in children and adolescents under 18 years of age has not beenestablished (2, 4, 11).

#### 8. Special warnings and precautions for use

- If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be consulted (4).
- In patients with a pathologically increased bleeding tendency (haemorrhagic diathesis) and concomitant anticoagulant and antiplatelet treatment, the medicinal product should only be used after consultation with a doctor (2, 4, 11).
- In patients with epilepsy: Ginkgo decreases seizure threshold (2, 4, 13).
- Use should be stopped prior to surgery due to a potential risk of increased bleeding or interaction with perioperative drug treatment (13).



## 9. Interactions with other medicinal products and other forms of interaction

- Concomitant use of *Ginkgo biloba* containing products and efavirenz is not recommended (4).
- Anticoagulants, platelet inhibitor, salicylates and other non-steroidal anti- inflammatory drugs: Because of the increased risk of bleeding, ginkgo should not be taken concurrently with these products (4).
- Anticonvulsants: Ginkgo components may decrease the anticonvulsant effect, concurrent use should be avoided (4).
- Buspirone, fluoxetine: Ginkgo given with these agents may cause hypomania (2).
- Cytochrome P450IA2/P4502D6/P4503A4 substrates: Ginkgo may affect drugs metabolized by these agents (2).
- Selective serotonin reuptake inhibitors (SSRIs): Ginkgo is often used to reverse the sexual side effects of SSRIs (2).
- Trazadone: Ginkgo with trazadone may cause coma (2).
- Anticoagulant/antiplatelet herbs: Ginkgo may increase the risk of bleeding when used with these herbs (2).
- St. John's wort: Ginkgo with St. John's wort can lead to hypomania (2).

#### Lab Test (2):

- Partial thromboplastin time, ASA tolerance test: Ginkgo may cause increased bleeding.
- Platelet activity: Ginkgo may decrease platelet activity.
- Prothrombin time, blood salicylate: Ginkgo may increase prothrombin time and blood salicylate.

#### **10.** Fertility, pregnancy and lactation

- The use during pregnancy and lactation should be avoided (3, 13).
- No fertility data available (1, 4).

#### 11. Effects on ability to drive and use machines

No adequate studies on the effect on the ability to drive and use machines have been performed (4).

#### **12.** Undesirable effects (4)

- If adverse reactions occur, a doctor or a pharmacist should be consulted.
- Bleeding of individual organs has been reported (eye, nose, cerebral and gastrointestinal haemorrhage).
- Headache and dizziness.



- Mild gastrointestinal complaints: diarrhoea, abdominal pain, nausea and vomiting.
- Hypersensitivity reactions (allergic shock) may occur, skin, subcutaneous tissue disorders and allergic skin reactions (erythema, oedema, itching, rash) may also occur.

#### 13. Overdose

No case of overdose has been reported.

#### 14. Relevant biological activities

Not required as per Egyptian guidelines for registration of herbal medicines.

#### **15.** Additional Information

#### 16. Date of compilation/last revision

20/02/2024



Egyptian Herbal Monograph

#### References

1	WHO monographs on selected medicinal plants (2007). Volume 1, 154 -167.
2	Skidmore-Roth, L. Mosby's Handbook of Herbs and Natural Supplements (2010). 4 <sup>th</sup> ed.,
	ISBN:978-0-323-05741-7.
3	Barnes J., Anderson L. A., Phillipson J. D. (2007). Herbal Medicines, 3 <sup>rd</sup> ed., Pharmaceutical Press,
	London, p. 293-298.
4	European Union herbal monograph on Ginkgo biloba L., (2015). EMA/HMPC/321097/2012.
	Committee on Herbal Medicinal Products (HMPC).
5	PDR for herbal medicines (2002). Montvale, NJ: Medical Economics Company, 2nd ed., ISBN 1-
	56363-361-2.
6	Li, W. and Fitzloffm J. F. (200.2). HPLC determination of flavonoids and terpene lactones in
U	commercial Ginkgo biloba products. J. Liquid Chromatography & Related Technologies, <b>25</b> (16),
	2501-2514, DOI: 10.1081/JLC-120014270.
7	Kulic, Z., Ritter, T., Rock, B., Elsaiser, J., Schneider, H. and Germer, S. (2022). A detailed view on the
	proantnocyaniains in Ginkgo extract EGD 761. Planta Mea., <b>88</b> (5), 398-404. doi: 10.1055/a-1379-
	Oa'dan, F., Mansoor, K., AL-Adham, L., Schmidt, M. and Nahrstedt, A. (2011). Proanthocyanidins
8	from <i>Ginkgo bilobg</i> leaf extract and their radical scavenging
	activity. <i>PharmaceuticalBiology</i> , <b>49</b> (5), 471 476. DOI: <u>10.3109/13880209.2010.523831</u> .
	Zhou, M., Hua, T., Ma, X., Sun, H. and Xu, L. (2019). Protein content and amino acids profile in 10
9	cultivars of ginkgo ( <i>Ginkgo biloba</i> L.) nut from China. <i>Royal Society Open Sci.</i> , <b>6</b> (3),181571. doi:
	10.1098/rsos.181571. PMID: 31032014; PMCID: PMC6458402.
10	Wang, F., Ye, S., Ding, Y., Ma, Z., Zhao, Q., Zang, M. and Li, Y. (2022). Research on structure and
	antioxidant activity of polysaccharides from <i>Ginkgo biloba</i> leaves. <i>Journal of Molecular Structure</i> ,
11	Natural Health Product, <i>Ginkgo biloba</i> (L.) (2018). Health Canada,
	http://webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=100⟨=eng
12	Kraft, K. and Hobbs, C. (2004). Pocket Guide to Herbal Medicine. Stuttgart; New York: Thieme.
	ISBN 3-13-126991-X (GTV), ISBN 1-58890-063-0 (TNY).
	Edwards, S. E., Rocha, I. D. C., Williamson, E. M. and Heinrich, M. (2015). Phytopharmacy: An
13	Evidence-Based Guide to Herbal Medicinal Products. Wiley Blackwell, ISBN: 978-1-118-54356-6.